Morgan Stanley
FDMT icon

Morgan Stanley’s 4D Molecular Therapeutics FDMT Stock Holding History

Morgan Stanley’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Buy
503,020
+157,610
+46% +$1.54M ﹤0.01% 4029
2026
Q1 		$3.22M Sell
345,410
-327,285
-49% -$2.85M ﹤0.01% 4429
2025
Q4 		$5.05M Sell
672,695
-163,216
-20% -$1.66M ﹤0.01% 4162
2025
Q3 		$7.26M Sell
835,911
-88,765
-10% -$531K ﹤0.01% 3835
2025
Q2 		$3.43M Sell
924,676
-852,067
-48% -$3M ﹤0.01% 4355
2025
Q1 		$5.74M Sell
1,776,743
-86,314
-5% -$407K ﹤0.01% 3810
2024
Q4 		$10.4M Buy
1,863,057
+160,718
+9% +$1.26M ﹤0.01% 3376
2024
Q3 		$18.4M Buy
1,702,339
+242,105
+17% +$4.02M ﹤0.01% 2885
2024
Q2 		$30.7M Sell
1,460,234
-89,492
-6% -$2.24M ﹤0.01% 2212
2024
Q1 		$49.4M Sell
1,549,726
-19,058
-1% -$486K ﹤0.01% 1772
2023
Q4 		$31.8M Buy
1,568,784
+102,916
+7% +$1.35M ﹤0.01% 2203
2023
Q3 		$18.7M Sell
1,465,868
-101,891
-6% -$1.7M ﹤0.01% 2528
2023
Q2 		$28.3M Sell
1,567,759
-174,118
-10% -$3.21M ﹤0.01% 2117
2023
Q1 		$29.9M Buy
1,741,877
+283,305
+19% +$5.51M ﹤0.01% 2012
2022
Q4 		$32.4M Sell
1,458,572
-563,001
-28% -$8.7M ﹤0.01% 1891
2022
Q3 		$16.3M Buy
2,021,573
+1,708,534
+546% +$15.5M ﹤0.01% 2417
2022
Q2 		$2.19M Sell
313,039
-106,997
-25% -$1.04M ﹤0.01% 4460
2022
Q1 		$6.35M Sell
420,036
-14,042
-3% -$221K ﹤0.01% 3421
2021
Q4 		$9.52M Buy
434,078
+65,627
+18% +$1.61M ﹤0.01% 3001
2021
Q3 		$9.94M Sell
368,451
-62,336
-14% -$1.78M ﹤0.01% 2894
2021
Q2 		$10.4M Buy
430,787
+158,641
+58% +$4.86M ﹤0.01% 2932
2021
Q1 		$11.8M Buy
272,146
+26,441
+11% +$1.17M ﹤0.01% 2487
2020
Q4 		$10.2M Buy
+245,705
New +$10.1M ﹤0.01% 2489

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Morgan Stanley's FDMT Position: Q2 2026 in Review

Morgan Stanley increased its 4D Molecular Therapeutics (FDMT) stake by 46% in Q2 2026, buying an estimated $1.54M and bringing the position to 503,020 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #4029.

Morgan Stanley first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $49.4M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Morgan Stanley held 503,020 shares of 4D Molecular Therapeutics worth $6.69M as of Q2 2026.
  • Morgan Stanley bought 157,610 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.54M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4029 holding.
  • Morgan Stanley first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's 4D Molecular Therapeutics position peaked at $49.4M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.